Table 6.
Sensitivity analysis of the combined model (CT-ECV + CEA + CA19-9 + NLR).
| Analysis type | Subgroup/adjustment | OR (95% CI) | AUC change |
|---|---|---|---|
| Base model | Total (n = 200) | 2.15 (1.68–2.75)* | 0.91 (0.86–0.96)* |
| Histology | |||
| Non-mucinous | (n = 168) | 2.12 (1.63–2.76)* | 0.90 (0.85–0.95)* |
| Mucinous | (n = 32) | 2.24 (1.58–3.18)* | 0.89 (0.82–0.96)* |
| Stage stratification | |||
| Stage I–II | (n = 120) | 2.08 (1.59–2.72)* | 0.88 (0.82–0.94)* |
| Stage III–IV | (n = 80) | 2.19 (1.67–2.87)* | 0.87 (0.81–0.93)* |
| Methodological adjustments | |||
| Multiple imputation | (Missing data) | 2.13 (1.65–2.74)* | ΔAUC = −0.01* |
| Outlier removal | (±3SD) | 2.11 (1.64–2.71)* | ΔAUC = −0.02* |
| Inter-observer variation | |||
| Radiologist A | (CT-ECV measurement) | 2.16 (1.67–2.79)* | 0.91 (0.86–0.96)* |
| Radiologist B | (CT-ECV measurement) | 2.14 (1.66–2.76)* | 0.90 (0.85–0.95)* |
AUC = area under the curve, CA19-9 = carbohydrate antigen 19-9, CEA = carcinoembryonic antigen, CI = confidence interval, CT-ECV = computed tomography-derived extracellular volume fraction, NLR = neutrophil-to-lymphocyte ratio, OR = odds ratio, SD = standard deviation.
*
Statistical significance, P < .05.